Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Rochester Dermatologic Surgery

Neither a doctor nor a teaching hospital

Research payments

$664,913

50 payments

Through program year 2025, Rochester Dermatologic Surgery is reported as receiving $664,913 in research payments, across 50 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $288,125 28
2024 Research $122,402 12
2023 Research $212,006 6
2022 Research $28,363 2
2021 Research $14,017 2

Breakdown

Who paid Research payments · program years 2021–2025
  1. Regeneron Pharmaceuticals, Inc. $339,350 26 payments
  2. Biofrontera Bioscience GmbH $274,609 16 payments
  3. Biofrontera Inc. $50,954 8 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients With Cutaneous Squamous Cell Carcinoma (CSCC) or Basal Cell Carcinoma (BCC) $253,155 13 payments
  2. Ala-Bcc-Ct013 $140,443 5 payments
  3. Ala-Ak-Ct018 $93,304 3 payments
  4. A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) $86,195 13 payments
  5. Ala-Ak-Ct019 $40,862 8 payments
  6. Study to Evaluate the Safety, Tolerability and Efficacy of Bf-200 Ala (Ameluz) in the Field-Directed Treatment of Actinic Keratosis (Ak) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using A Rhodoled Lamp $28,426 2 payments
  7. A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz ) and BF-RhodoLED in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT). $14,017 2 payments
  8. Study to Evaluate the Safety and Efficacy Ofbf-200Ala(Ameluz) and Bf-Rhodoled in the Treatment of Superficialbasal Cell Carcinoma(Sbcc) With Photodynamic Therapy (PDT). $4,510 2 payments
  9. A Non-Ranodmized, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Bf-200 Ala (Ameluz) and Bf-Rhodoled XL in the Expanded Field-Directed Treatment of Actinic Keratosis on the Face and Scalp With Photodynamic Therapy (PDT) $3,250 1 payment
  10. Activation of Ameluz With BBL Heroic for the Treatment of Actinic Keratoses and Photodamage $751 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record